数据
资源
版本对比
免费注册
预约演示
免费注册
Insulet Appoints Ana Maria Chadwick as Chief Financial Officer
2024-03-20
·
BioSpace
高管变更
ACTON, Mass.--(BUSINESS WIRE)--
Insulet Corporation
(NASDAQ: PODD) (
Insulet
or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that Ana Maria Chadwick has been appointed Executive Vice President, Chief Financial Officer and Treasurer, effective April 22, 2024. Today’s announcement concludes an extensive search process conducted by the Company. This press release features multimedia. View the full release here: Ana Maria Chadwick, Chief Financial Officer (Photo: Business Wire) “We are thrilled to welcome Ana to
Insulet
,” said Jim Hollingshead, President and Chief Executive Officer. “She is an experienced public company CFO, and her achievements throughout her career demonstrate that she is a proven, highly accomplished, and versatile executive. Ana is known for her insight, intellectual agility, and compelling and collaborative leadership. She will be a strong addition to our leadership team as we continue to scale and expand our business.” A talented finance executive with 30 years of experience propelling growth for top-tier global organizations, Ms. Chadwick is currently Executive Vice President and CFO of Pitney Bowes, where she has played an integral role in the company’s transformation from a 100-year-old mailing solutions operation into a technology-enabled growth business. Previously, she spent more than 27 years at
GE
, where she held a variety of financial and operational roles including CEO and COO of GE Capital Global Legacy Solutions and CFO of GE Capital Energy Financial Services. Other roles included Controller of GE Capital Americas. Over the span of her career, she has led large and dynamic finance teams, overseeing financial reporting, and driving financial and operational efficiencies in the U.S., Latin America, and Europe. In addition to broad finance and accounting experience, Ms. Chadwick brings a deep understanding of capital markets, business strategy, investor relations, and tax policy. Ms. Chadwick serves on the board of directors of Dollar General and chairs the Audit Committee, is chair of the Pitney Bowes ILC Bank in Utah, and is on the board of LiveGirl, Inc. where she mentors and dedicates time to provide greater opportunities for underprivileged girls. She is a former member of both
GE
’s Hispanic Forum and Women’s Network. Ms. Chadwick received her Bachelor of Arts in Economics and Business Administration from
American University
in Washington, D.C. “I am excited to join the
Insulet
team and help the Company advance its critical mission of improving the lives of people with
diabetes
,” said Ms. Chadwick. “I look forward to working with Jim and the talented team to build on
Insulet
’s strong financial foundation, further driving growth, profitability, and value for shareholders.” Lauren Budden, who has been serving as the Company’s Interim CFO and Treasurer, will continue in her role as Group Vice President, Chief Accounting Officer and Controller. Mr. Hollingshead continued, “On behalf of the Board of Directors and the entire management team, I thank Lauren for taking on the additional role of Interim CFO. We are grateful for Lauren’s exceptional leadership and providing continuity during our search.” About
Insulet Corporation
:
Insulet Corporation
(NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with
diabetes
and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional
insulin
delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop
insulin
delivery, without the need to see or handle a needle.
Insulet
’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone or the Omnipod 5 Controller.
Insulet
also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, please visit: insulet.com and omnipod.com. ©2024
Insulet Corporation
. All rights reserved. View source version on businesswire.com: Contacts Investor Relations: Deborah R. Gordon Vice President, Investor Relations (978) 600-7717 dgordon@insulet.com Media: Angela Geryak Wiczek Senior Director, Corporate Communications (978) 932-0611 awiczek@insulet.com Source:
Insulet Corporation
Smart Multimedia Gallery Photo Ana Maria Chadwick, Chief Financial Officer (Photo: Business Wire) Logo View this news release and multimedia online at:
更多内容,
请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
机构
Insulet Corp.
Gopal Enterprises
American University
适应症
糖尿病
靶点
-
药物
Insulin (glucose-responsive smart patch)(North Carolina State University/University of North Carolina)
标准版
¥
16800
元/账号/年
新药情报库 | 省钱又好用!
立即使用
热门报告
全球潜力靶点及FIC产品研究调研报告
智慧芽生物医药
肿瘤领域药物开发早期热门靶点研究报告(AACR 2023-2024)
智慧芽生物医药
siRNA药物Amvuttra专利调研实务指南
智慧芽生物医药
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
开始免费试用
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。
试用数据服务